Guest Contributor


Organizations:
AvidBiologics Inc, Lumira Capital, MaRS Innovation, MaRS Investment Accelerator Fund, National Research Council, Rosseau Asset Management, University Health Network, Western Univ, and YM Biosciences Inc

AvidBiologics completes VC financing round

Guest Contributor
October 14, 2014

Toronto-based AvidBiologics Inc has closed a financing round to move its antibody-drug conjugate (ADC) technologies into clinical trials. The privately held firm — a 2011 spinout from YM BioSciences Inc — secured an unspecified amount of financing from Lumira Capital (lead), MaRS Investment Accelerator Fund, MaRS Innovation, Rosseau Asset Management and the company's founding investors. The firm's ADC therapeutics target solid tumors being developed in partnership with Western Univ, University Health Network and National Research Council....


Other News

Ontario's MRI to foot bill for interest on MaRS loan

XRCC to collaborate with GreenCentre Canada

Universities and colleges enter collaboration agreement

New stroke drug receives $6.6 million for clinical trials






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.